The combination of cAMP enhancer Forskolin, ISX9, CHIR99021, and I-BET151, along with dual antiplatelet therapy (DAPT), can upregulate the expression levels of the Ngn2, Ascl1, Brn2, and MAP2 genes in U87 MG cells and reprograms the tumor cells to neuronal morphology without undergoing the intermediate pluripotent state, which can lead to the inhibition of U87MG cell growth and the formation of tumor-like spheroids (100). The gene discussed is MAP2; the disease is neoplasm.